HSBC Holdings
AVIR icon

HSBC Holdings’s Atea Pharmaceuticals AVIR Stock Holding History

HSBC Holdings’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
258,989
+17,715
+7% +$81.4K ﹤0.01% 1701
2025
Q4 		$855K Buy
241,274
+34,915
+17% +$111K ﹤0.01% 2028
2025
Q3 		$590K Buy
206,359
+10,577
+5% +$36.1K ﹤0.01% 2022
2025
Q2 		$719K Sell
195,782
-5,451
-3% -$16.3K ﹤0.01% 1969
2025
Q1 		$604K Buy
201,233
+39,023
+24% +$122K ﹤0.01% 1991
2024
Q4 		$546K Buy
162,210
+2,610
+2% +$8.67K ﹤0.01% 2125
2024
Q3 		$539K Buy
159,600
+1,491
+0.9% +$5.41K ﹤0.01% 1977
2024
Q2 		$518K Sell
158,109
-13,259
-8% -$49.4K ﹤0.01% 1953
2024
Q1 		$692K Sell
171,368
-9,003
-5% -$35.2K ﹤0.01% 1941
2023
Q4 		$554K Buy
180,371
+168,273
+1,391% +$510K ﹤0.01% 2011
2023
Q3 		$36K Buy
+12,098
New +$41.2K ﹤0.01% 2654
2022
Q2 		– Sell
-11,717
Closed -$83K – 3231
2022
Q1 		$83K Hold
11,717
– – ﹤0.01% 3151
2021
Q4 		$105K Buy
+11,717
New +$183K ﹤0.01% 3135

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HSBC Holdings's AVIR Position: Q1 2026 in Review

HSBC Holdings increased its Atea Pharmaceuticals (AVIR) stake by 7.3% in Q1 2026, buying an estimated $81.4K and bringing the position to 258,989 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

HSBC Holdings first reported a position in AVIR in Q4 2021 and has held it in 13 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • HSBC Holdings held 258,989 shares of Atea Pharmaceuticals worth $1.38M as of Q1 2026.
  • HSBC Holdings bought 17,715 Atea Pharmaceuticals shares in Q1 2026, an estimated $81.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1701 holding.
  • HSBC Holdings first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.